Sylvant

Chemical Namesiltuximab
Dosage FormInjection (intravenous; 100mg, 400mg)
Drug ClassReceptor antagonists
SystemBlood
CompanyJanssen Biotech
Approval Year2014

Indication

  • For the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Sylvant (siltuximab) Prescribing Information 2014Janssen Biotech, Inc. Horsham, PA 19044